Introduction
Atrial fibrillation (AF) is a source of considerable morbidity and mortality. In 1995, Wijffels et al. revealed that AF modified atrial properties so that AF maintains itself more readily, a phenomenon called electrical remodeling and described as “AF begets AF.”1 The electric remodeling during AF involves decrease in the atrial effective refractory period (ERP), action potential (AP) duration,2-5 and/or ERP adaptation to heart rate,1,6 as well as decreased atrial conduction velocity (CV).2,3,5 Voltage-gated sodium channels are transiently activated on depolarization of the cardiac cell membrane and are responsible for the rapid upstroke of cardiac AP, and for rapid impulse conduction through cardiac tissue.7,8 Inhibition of cardiac sodium current (I_Na) slows down CV, which as a single factor reduces wavelength (defined as the product of CV and ERP) and should promote AF induction or atrial flutter.9

Activation of the renin-angiotensin system (RAS) plays an important role in atrial electrical remodeling (AER). The purpose of the present study was to evaluate the effects of irbesartan on cardiac sodium current (I_Na) in a canine model of atrial fibrillation.

Materials and methods: Eighteen dogs were randomized into sham, pacing or pacing+irbesartan groups (n = 6 in each group). The dogs in the pacing and irbesartan group were paced at 500 bpm for two weeks. Irbesartan (60 mg·kg⁻¹·d⁻¹) was administered orally in the pacing+irbesartan groups. I_Na was recorded using the whole-cell patch clamp technique from canine atrial myocytes. The expressions of cardiac Na⁺ channels (Nav1.5) mRNA were semi-quantified by reverse transcription-polymerase chain reaction.

Results: Our results showed that I_Na density and Nav1.5 mRNA expression in the pacing group decreased significantly (p < 0.05 vs. sham). However, rapid atrial pacing had no effects on the half-activation voltage (V1/2act) and half-inactivation voltage (V1/2inact) of I_Na (p > 0.05 vs. sham). Irbesartan significantly increased I_Na densities and gene expression and hyperpolarized V1/2act without concomitant changes in V1/2inact.

Conclusions: Irbesartan significantly increased I_Na densities, which contributed to improving intra-atrial conduction and prevented the induction and promotion of AF in atrial pacing dogs.

Keywords
Atrial electrical remodeling, irbesartan, renin-angiotensin system, sodium current, Nav1.5 α subunit

Date received: 5 December 2016; accepted: 24 December 2017
calcium, alters the potassium conductance, and induces the genesis of transient inward currents. Ang II can also decrease SCN5A transcription and current through production of H2O2 resulting in nuclear factor kappa B (NF-κB) binding to the sodium channel promoter. Therefore, Ang II has a high arrhythmogenic activity and may play an important role in the pathophysiology of atrial fibrillation, and inhibition of Ang II may prevent the development of atrial electrical remodeling (AER).

Angiotensin II receptor blockers (ARBs) are medications frequently used in the treatment of congestive heart failure and hypertension and have several cardiac electrophysiological effects. Previous studies have shown that the ARB irbesartan was found to contribute to maintenance of sinus rhythm after successful electrical cardioversion and prevented the shortening of the atrial ERP during rapid atrial pacing. In addition, irbesartan suppresses atrial fibrosis and AF development in a canine atrial tachycardia remodeling model. Furthermore, irbesartan attenuated the hypotonic solution-induced increase in rectifier potassium currents induced by stretching atrial myocytes. Previous studies led to the conclusion that atrial electrical and structural remodeling could be prevented by irbesartan and Ang-(1–7); meanwhile, chronic rapid atrial pacing, a concomitant reduction in AF vulnerability in a canine model, could be observed.

The procedure for isolating cells was the same as used in previous research. On study days, the dogs were anesthetized with pentobarbital and ventilated as above. A median sternotomy was performed. At room temperature the hearts were removed and immersed in Ca2+-free Tyrode’s solution. Whole-cell INa was recorded at room temperature using the patch-clamp technique as described previously. 

Materials and methods

Animal model

Approval for use of the animals in this study was attained from the Experimental Animal Administration Committee of Tianjin Medical University and Tianjin Municipal Commission for Experimental Animal Control. Eighteen mongrel dogs of either sex, weighing between 11 and 15 kg, were randomly assigned to three groups. In the pacing+irbesartan group (n = 6), oral administration of irbesartan (60mg·kg⁻¹·d⁻¹) was continued to the end of the study. The dogs in the sham (n = 6) and pacing group (n = 6) did not receive irbesartan. Dogs within the pacing and pacing+irbesartan groups were paced at 500 beats per minute (bpm) (120 ms cycle length) with 0.2 ms square-wave pulses at twice-threshold current for 14 days. Sham animals were instrumented without pacing and were examined for 14 days following pacemaker insertion.

We used a previously described method to produce dogs with sustained AF. In brief, all dogs were anesthetized with sodium pentobarbital (30 mg·kg⁻¹, intravenously). Under sterile technique, a unipolar screw-in St. Jude J pacemaker was inserted through the right jugular vein and the distal end of the lead was screwed in the right atrium. Initial atrial capture was verified using an external stimulator (TOP2001, Hongtong Co, Shanghai, China). The proximal end of the pacing lead was connected to a tachy-pacing generator (made in Shanghai Fudan University, China), which was inserted into a subcutaneous pocket in the neck. Twenty-four hours was allowed for the lead to stabilize. The pacemaker was programmed to stimulate the atrium at 500bpm (120 ms cycle length). Surface electrocardiograms (ECGs) were verified after 24 hours, and then every other day, to ensure continuous 1:1 atrial capture. Direct systolic blood pressure was determined during anesthesia at baseline, and 14 days following atrial pacing.

Single-cell electrophysiology

The left circumflex artery was cannulated, and the hearts were immersed in 4°C Ca2+-free Tyrode’s solution for 5 minutes until cardiac arrest and the effluent was clear. Any leaking arterial branches were ligated using silk thread to ensure adequate perfusion. The tissue was then perfused at 25 ml/min with Ca2+-free Tyrode’s solution for 20 minutes, followed by a 40-minute perfusion using the same solution containing collagenase (100 U/ml, CLSII, Worthington Biochemical, USA), and 0.5% bovine serum albumin (BSA) (Sigma Chemical Co, USA). The left atrium became opaque and mottled in appearance and tissue from a well-perfused region was removed using a forceps, gently triturated, and maintained at room temperature in a high-K+ storage solution.

High output of isolating atrial myocytes was obtained in our experiments. Only those quiescent rod-shaped cells lacking membrane deformities and showing clear cross-striations were studied. Five minutes after cell adhesion, cells were superfused with Tyrode’s solution (3 ml/min) for 5 minutes, followed by extracellular solution for the recording of INa, at the same velocity and time of flow. Recordings of INa were obtained 5 minutes following membrane rupture.

Data acquisition

Whole-cell INa was recorded at room temperature using the patch-clamp technique as described previously.
Borosilicate glass electrodes with tip resistances of 2.0 to 4.0 MΩ were connected to a patch clamp amplifier (Axopatch 200B, Axon Instruments, USA). Data were sampled by using an analog-to-digital converter (Digidata 1200, Axon Instruments, USA) and stored for subsequent analyses. Inactivation of current amplitude was measured on the basis of differences between the peak current and steady-state current at the end of a depolarizing pulse. After establishing the whole-cell configuration, series resistance (estimated from the decay of the capacitive transient) was typically two to three times the pipette resistance (<6 MΩ) and was electronically compensated. Several minutes after seal formation, the membrane was ruptured by gentle suction to establish the whole-cell configuration for voltage clamping. Series resistance (Rs) was electronically compensated to minimize voltage errors. Voltage command pulses were generated from the Digidata 1200 and controlled using pClamp7.0 software. Current signals were low-pass filtered at 0.5 kHz and the sampling frequency was 10 Hz for recording of I_{Na}. To control for differences in cell size, current values were normalized to membrane capacitance (Cm), expressed as current densities (pA/pF).

Current-voltage relationships were determined in the extracellular solution over a voltage range of −80 to +60 mV with 10-mV increments. Voltage-dependent activation curves of I_{Na} were fitted with a Boltzmann equation:

\[ g_{\text{Na}} \left( \text{or } I_{\text{Na}} \right)_{\text{max}} = \frac{1}{1+\exp\left(\frac{V-V_{1/2}}{\kappa}\right)} \]

where \( V_{1/2} \) is the potential at which half maximum activation or inactivation occurs and \( \kappa \) is the slope factor. Steady-state inactivation was measured utilizing a standard dual-pulse protocol. Cells were held at −120 mV prior to evoking a 1-second conditioning pulse immediately followed by a 40-ms pulse to −40 mV with 5-mV increments to measure sodium current. Normalized currents were plotted as a function of conditioning step voltage and were fitted to a sodium current. Normalized currents were plotted as a function of conditioning step voltage and were fitted to a sodium current.

**Solutions**

Ca\(^{2+}\)-free Tyrode’s solution contained (mM) KCl 5.4, MgCl\(_2\) 0.8, NaH\(_2\)PO\(_4\) 0.33, NaCl 136, HEPES 10, glucose 10, and pH 7.4 adjusted with NaOH. High-K\(^+\) storage solution contained (mM) KCl 20, KH\(_2\)PO\(_4\) 10, taurine 10, L-glutamic acid 70, EGTA 10, glucose 10, BSA 0.5% (5 mg/ml, Roche Group), and pH 7.4 adjusted with KOH.

I\(_{Na}\) extracellular solution contained (mM) choline-Cl 110, CsCl 20, MgCl\(_2\) 1.0, HEPES 10, glucose 10, NaCl 10, CaCl\(_2\) 1.0, and pH 7.4 adjusted using NaOH. The pipette solution for I_{Na} recording was (mM) CsCl 20, tetraethyl ammonium chloride 20, aspartic acid 80, CsOH 80, MgCl\(_2\) 1, HEPES 10, EGTA 10, Mg\(_2\)ATP 5, Na\(_2\)GTP 0.1, Na\(_2\)phosphocreatine 5, and pH 7.25 adjusted with CsOH. All solutions used for dissection and perfusion were equilibrated using 100% O\(_2\).

**RNA extraction and reverse transcription-polymerase chain reaction (RT-PCR) analyses**

Following cardiotomy, the left atria were excised for subsequent molecular biological studies. Specimens were snap-frozen in liquid nitrogen and stored separately at −80°C for further analyses. One aliquot of each tissue was used to investigate the mRNA expression of the Nav1.5 α subunit. Total RNA was extracted from 100 mg atrial tissues using a total RNA extraction kit (New Industry Co, Canada). Integrity of RNA was confirmed by agarose gel electrophoresis, the quantity of RNA was assessed spectrophotometrically (UV-240, Shimadzu Co, Japan) at a wavelength of 260 nm, and RNA was stored at −80°C for later analysis.

Specific oligonucleotide primer pairs for the amplification of Nav1.5 were designed according to GeneBank sequences. β-actin was utilized as the loading control. GeneBank accession numbers were NM-001002994 and AF021873 (β-actin). Gene-specific primers were designed using the Gene Runner software package. The specific primers were as follows: 5’-TAAATGTCTCTCTGCTGTG-3’ (Nav1.5 α subunit, 424 bp), 5’-GGACCCTGACTGACTACCTC-3’ (Nav1.5 α subunit, 536 bp). Primers were purchased from Shanghai Yingjun Gen-Tech Ltd (Shanghai, China). A total of 200 ng of total RNA underwent RT-PCR using a commercially available kit (TaKaRa Co, Japan). PCR involved the following steps: initial denaturation at 94°C for 5 minutes followed by 37 cycles of denaturation for 40 seconds at 94°C, annealing for 40 seconds at 51°C, and elongation for 30 seconds at 72°C with a final extension at 72°C for 5 minutes. Product (5 μl) was analyzed using 1% agarose gel electrophoresis. The resultant target gene sequence was identified using Shanghai Yingjun Gen-Tech Ltd (Shanghai, China).

**Statistical analyses**

In order to ensure data validity from voltage-clamp studies, similar numbers of cells from each heart were studied utilizing the same protocol (i.e., cells were distributed evenly across dogs). Grouped data are presented as mean±SEM. Statistical comparisons among groups were performed by analysis of variance. Differences with a two-tailed \( p < 0.05 \) were considered statistically significant. All authors had full access to the data and take responsibility for their integrity.

**Results**

**Hemodynamic parameters**

No significant differences in ventricular rate or systolic blood pressure among the three groups were observed at baseline \( (p > 0.05) \), with no differences found during pacing.
Heart rate and blood pressure were also unchanged by rapid pacing within each group (p > 0.05). Heart rate and blood pressure were also unchanged by rapid pacing within each group (p > 0.05).

INa densities

To avoid contaminating the effects of time-dependent changes in INa I-V, all protocols were performed by utilizing the same sequence: beginning with the INa density-voltage relationship, immediately followed by analyses of voltage-dependent inactivation.

Figure 1 illustrates the overall results for INa current densities. Peak INa density is shown as a function of test potential. The peak INa densities (as is shown in Table 1) were −61.56±14.17 pA/pF (14 cells) in the sham, −32.65±10.92 pA/pF (28 cells) in the pacing, and −65.24±14.79 pA/pF (13 cells) in the pacing+irbesartan groups. INa was significantly decreased at all voltages (−60 mV to +35 mV) in the pacing group but the form of the I-V curve did not change compared with the sham group (p < 0.05). The reduction of mean INa density was significantly prevented by irbesartan, and peak current densities increased by 99.82% compared with the pacing group (p < 0.05). Cell capacitance averaged 69.15±19.16 pF (n = 14) in the sham, 73.48±13.01 pF (n = 28) in the pacing and 76.46±22.79 pF (n = 13) in the pacing+irbesartan groups.

**Activation and inactivation characteristics of INa in isolated atrial myocytes**

Figure 2 depicts the steady-state activation curve of INa. Table 2 summarizes the shifts in activation and inactivation variables. Voltage-dependent activation data were well-fitted using the Boltzmann equation. In the present experiment, rapid pacing did not alter half-activation voltage (V1/2act) (membrane voltage (Vm) at which half-activation occurs) compared with the sham group (p > 0.05). V1/2act in the pacing+irbesartan group was more negative compared with the sham or pacing groups (p < 0.05). The activation slope factor κact, V1/2inact (Vm at which half-inactivation occurs) and inactivation slope factor κinact were not significantly different among the three groups, indicating that rapid pacing and irbesartan have no significant effects on κact, V1/2inact or κinact of INa (Figure 3).

**Nav1.5 α subunit mRNA expression**

INa in the heart is primarily generated by Nav1.5. The α subunit is the principal component of Nav1.5 forming the pore and all essential gating elements, and is sufficient by itself for generating INa in heterologous expression systems. Figure 4(a) shows a gel obtained by semiquantitative RT-PCR for the Nav1.5 α subunit. Lanes S, P and IB are PCR products from the sham, pacing and pacing+irbesartan groups obtained by the addition of 5 μl of the internal standard along with 5 μl of Nav1.5 α subunit PCR product, respectively. DL2000 is the DNA marker. The upper band in each lane represents the Nav1.5 α subunit mRNA product (424bp), and the lower band is the internal standard signal (β-actin, 536 bp). Figure 4(b) shows the mean±SEM of Nav1.5 α subunit mRNA levels in six hearts (one

### Table 1. Hemodynamic parameters before and after pacing in each group.

| Grouping (n = 6 in each group) | Heart rate (bpm) | Systolic blood pressure (mmHg) |
|-------------------------------|-----------------|-------------------------------|
|                               | Before pacing   | Paced for 14 days  | p    | Before pacing   | Paced for 14 days  | p    |
| Sham                          | 165.8±9.6       | 187.0±13.0          | >0.05| 134.0±7.0       | 138.0±6.0          | >0.05|
| Pacing                        | 171.6±11.9      | 188.0±20.0          | >0.05| 140.0±10.0      | 138.0±8.0          | >0.05|
| Irbesartan                    | 168.0±10.5      | 186.0±11.0          | >0.05| 135.0±10.0      | 136.0±9.0          | >0.05|
| p                             | >0.05           | >0.05              |      | >0.05           | >0.05              |      |

Sham: sham group; Pacing: pacing group; Irbesartan: pacing+irbesartan group; bpm: beats per minute.
independent determination per heart) from each group of dogs. Nav1.5 α subunit mRNA expression was decreased by 54.83% after 14 days of rapid atrial pacing (p < 0.05 vs. sham). The observed changes in mRNA levels are parallel to changes in I_Na densities. Irbesartan prevented the decrease of Nav1.5 α subunit mRNA expression compared with the paced group (p < 0.05).

Discussion

Key findings

A brief summary can be drawn from the key findings of the present study, that is, following pacing, I_Na density and mRNA expression of the Nav1.5 α subunit were decreased; irbesartan increased I_Na densities and hyperpolarized V_1/2act. Meanwhile, it did not significantly affect κ_act or the inactivation characteristics of I_Na when compared with the pacing group. Irbesartan prevented downregulation of mRNA expression of the Nav1.5 α subunit in the pacing group.

Effects of rapid atrial pacing on I_Na and Nav1.5 α subunit gene expression

As the key structure of excitability in conduction of electrical impulses in cardiac tissue, the voltage-gated sodium channel is targeted by a series of anti-arrhythmics. The Nav1.5 α subunit is the principal component of cardiac Na⁺ channels, forming the pore and all essential gating elements and is sufficient to generate I_Na by itself in heterologous expression systems. Our previous research has shown that reductions in I_Na density and Nav1.5 α subunit gene expression potentially accounted for slowing of atrial conduction in a canine model of chronic AF.17 Decreased conduction and ERP results in shorter wavelength (defined as the product of CV and ERP) and increases the number of wavelengths that can coexist in the given atrial dimension. Thus, it increases the likelihood of sustained AF.

Effects of irbesartan on I_Na and Nav1.5 α subunit mRNA expression

Activation of the RAS contributes to development and maintenance of AF.19,20 Ang II has been shown to stimulate various growth factors inducing development and maintenance of AER by acting on type 1 receptors10 and may have cellular electrophysiologic effects on the modulation of ion channels in cardiac myocytes.21,22 Ang II may increase intracellular calcium concentration,23,24 and intracellular calcium overload can downregulate Na⁺ channels, which may lead to decrease of I_Na and conduction delay deficits.25 It is also reported that Ang II antagonists may exert favorable anti-arrhythmic effects in AF.26 Li et al. found that imidapril markedly increases I_Na density of ventricular myocytes from healed myocardial infarction in rabbits.27 Thus, they suggested that increased I_Na density may underlie the anti-arrhythmic effects of imidapril. We previously reported that Ang-(1–7) treatment significantly increased I_Na densities but had no effect on the expression of the Nav1.5 gene.17 However, the effects of irbesartan on I_Na or Nav1.5 mRNA expression are not

---

**Table 2.** I_Na densities and steady-state activation and inactivation of I_Na.

| Grouping          | I_Na densities (pA/pF) | Activation | Inactivation |
|-------------------|------------------------|------------|-------------|
|                   | n                      | κ_act | V_1/2act (mV) | n          | κ_inact | V_1/2inact (mV) | n          |
| Sham              | −61.56±14.17           | 14    | 0.75±0.99    | 14         | 4.16±0.81 | −84.89±4.05    | 12         |
| Pacing            | −32.65±10.92a          | 28    | 1.77±1.31    | 28         | 4.57±0.48 | −89.16±5.40    | 21         |
| Irbesartan        | −65.24±14.79b          | 13    | 0.85±1.09    | 13         | 4.61±0.76 | −88.31±9.12    | 9          |

All data shown represent mean±SEM. a p < 0.01 vs. corresponding value in the sham group. b p < 0.05 vs. corresponding value in the pacing group. c p < 0.05 vs. corresponding value in the sham and pacing groups. Sham: sham group; Pacing: pacing group; Irbesartan: pacing+irbesartan group; I_Na: cardiac sodium current; pA/pF: current densities; κ_act: activation slope factor; V_1/2act: half activation voltage.
clear. Our present data suggest that irbesartan can increase INa and Nav1.5 α subunit mRNA expression in a canine model of atrial tachycardia. We speculate that Ang II-induced intracellular calcium overload, which leads to decrease of INa and conduction delay deficits, may be partially responsible for this effect.25

AF is generally considered to be a re-entrant arrhythmia, and the stability of AF is classically related to wavelength. As previously discussed, wavelength is defined as the product of CV and ERP. Therefore, modification of ERP or CV can affect AF vulnerability and stability.28 Irbesartan increased INa and contributed to the increase of CV, the lengthening of reentry wavelength as well as the decreasing in the number of wavelengths. Thus, treatment with irbesartan could have the potential to reduce AF incidence. We also found that irbesartan upregulated Nav1.5 α subunit mRNA expression. These findings suggest that increased Nav1.5 gene levels by irbesartan, at least in part, are potentially responsible for changes in INa densities.

**Effects of irbesartan on activation and inactivation characteristics of INa**

Our previous research has shown that rapid atrial pacing has no effects on voltage-dependent activation of INa and Ang-(1–7) resulted in more negative test potentials.17 The present study revealed that irbesartan had a similar effect as Ang-(1–7), which suggested an increased conductance at a particular membrane potential.29 Such shifts induced faster activation kinetics and current augmentation at potentials closer to the threshold for activation and could actually indicate an enhancement of the current amplitude.29 And this could be speculated as a key reason why the agent increased INa densities.

There is no significant difference in comparison of voltage-dependent inactivation of INa among the three groups, which is consistent with the previous study.6 However, in human AF, myocardium in the inactivation curve was shifted to more positive voltages, which could increase sodium channel availability at the resting potential and increase CV.30 There are many reasons contributing to these contrasting results of human and animal models of AF: differences of AF types (experimental vs. clinical AF), underlying cardiac disease, anti-arrhythmic drugs, or interspecies differences.

Li and colleagues demonstrated that imidapril hyperpolarized V1/2inact of INa in rabbit ventricular myocytes.27 Kim et al. reported that telmisartan significantly delayed the
inactivation of the voltage-gated Na⁺ channel, causing cytosolic Na⁺ overload, prolonged AP duration, and subsequent Ca²⁺ overload in ventricular cardiomyocytes of male Sprague Dawley rats. However, we did not find any difference in our data. We thus concluded that irbesartan did not have obvious effects on the inactivation characteristics of INa. Therefore, our conclusion varied from the above-mentioned one. The difference in conclusions might be caused by several issues, such as interspecies differences, differences in the animal models, time of drug administration, different drugs, or differences between atrial and ventricular myocardium. In addition, there was no alteration of slope factor κact and κinact shown in the three groups, which suggested that the intrinsic voltage of the channel was unaffected by pacing or drug treatment.

**Study limitations**

One of the limitations of the present study is that we did not assess ventricular function using echocardiography. Since ventricular rate and blood pressure were not significantly changed by rapid atrial pacing among the three groups, ventricular tachycardia-induced left ventricular dysfunction likely did not have a significant effect on the results of these experiments. Furthermore, in our study only the left atria were analyzed. Therefore, responses of the right atrium to irbesartan remain unknown. Research on the sodium channel protein expression is still under way.

**Conclusions**

Irbesartan is a powerful activator of atrial sodium channels by selectively shifting the voltage-activation relationship of INa to hyperpolarized potential or upregulating Nav1.5 mRNA expression. Therefore, irbesartan may contribute to the improvement of intra-atrial conduction and the prevention of induction and promotion of AF in atrial pacing dogs.

**Declaration of conflicting interests**

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Program of the Natural Science Foundation of China (grant number 30770863).

**References**

1. Wijffels MC, Kirchhof CJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. *Circulation* 1995; 92: 1954–1968.
2. Gaspo R, Bosch RF, Talajic M, et al. Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model. *Circulation* 1997; 96: 4027–4035.
3. Daoud EG, Bogun F, Goyal R, et al. Effect of atrial fibrillation on atrial refractoriness in humans. *Circulation* 1996; 94: 1600–1606.
4. Goette A, Honeycutt C and Langberg JJ. Electrical remodeling in atrial fibrillation. Time course and mechanisms. *Circulation* 1996; 94: 2968–2974.
5. Yue L, Feng J, Gaspo R, et al. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. *Circ Res* 1997; 81: 512–525.
6. Gaspo R, Bosch RF, Bou-Abboud E, et al. Tachycardia-induced changes in sodium current in a chronic dog model of atrial fibrillation. *Cir Res* 1997; 81: 1045–1052.
7. Kléber AG and Rudy Y. Basic mechanisms of cardiac impulse propagation and associated arrhythmias. *Physiol Rev* 2004; 84: 431–488.
8. Ding GL, Hu D, Liu X, et al. Suppression of sodium current by arachidonic acid in atrial myocytes from patients with coronary heart disease. *Pacing Clin Electrophysiol* 2000; 23: 1820–1822.
9. Shang LL, Sanjay S, Pfahnl AE, et al. NF-kappaB-dependent transcriptional regulation of the cardiac scn5a sodium channel by angiotensin II. *Am J Physiol Cell Physiol* 2008; 294: C372–C379.
10. Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. *Circulation* 2000; 101: 2612–2617.
11. Touyz RM, Sventek P, Lariviére R, et al. Cytosolic calcium changes induced by angiotensin II in neonatal rat atrial and ventricular cardiomyocytes are mediated via angiotensin II subtype I receptors. *Hypertension* 1996; 27: 1090–1096.
12. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study. *Circulation* 2002; 106: 331–336.
13. Kataoka N, Nishida K, Kinoshita K, et al. Effect of irbesartan on development of atrial fibrosis and atrial fibrillation in a canine atrial tachycardia model with left ventricular dysfunction, association with p53. *Heart Vessels* 2016; 31: 2053–2060.
14. Wu J, Ding WG, Zhao J, et al. Irbesartan-mediated AT1 receptor blockade attenuates hyposmotic-induced enhancement of IKs current and prevents shortening of action potential duration in atrial myocytes. *J Renin Angiotensin Aldosterone Syst* 2014; 15: 341–347.
15. Liu E, Xu Z, Li J, et al. Enalapril, irbesartan, and angiotensin-(1–7) prevent atrial tachycardia-induced ionic remodeling. *Int J Cardiol* 2011; 146: 364–370.
16. Liu E, Yang S, Xu Z, et al. Angiotensin-(1–7) prevents atrial fibrosis and atrial fibrillation in long-term atrial tachycardia dogs. *Regul Pept* 2010; 162: 73–78.
17. Wang X and Li G. Angiotensin-(1–7) prevent atrial tachycardia-induced sodium channel remodeling. *Pacing Clin Electrophysiol* 2014; 37: 1349–1356.
18. Nerbonne JM and Kass RS. Molecular physiology of cardiac repolarization. *Physiol Rev* 2005; 85: 1205–1253.
19. Willems R, Sipido KR, Holemans P, et al. Different patterns of angiotensin II and atrial natriuretic peptide secretion in a sheep model of atrial fibrillation. *J Cardiovasc Electrophysiol* 2001; 12: 1387–1392.
20. Ferrario CM. Angiotensin-converting enzyme 2 and angiotensin-(1–7): An evolving story in cardiovascular regulation. *Hypertension* 2006; 47: 515–521.
21. De Mello WC. Intracellular angiotensin II regulates the inward calcium current in cardiac myocytes. *Hypertension* 1998; 32: 9769–9782.
22. Daleau P and Turgeon J. Angiotensin II modulates the delayed rectifier potassium current of guinea pig ventricular myocytes. *Pflugers Arch* 1994; 427: 553–555.
23. Allessie MA, Boyden PA, Camm AJ, et al. Pathophysiology and prevention of atrial fibrillation. *Circulation* 2001; 103: 769–777.
24. Lea JP, Jin SG, Roberts BR, et al. Angiotensin II stimulates calcineurin activity in proximal tubule epithelia through AT-1 receptor-mediated tyrosine phosphorylation of the PLC-gamma isoform. *J Am Soc Nephrol* 2002; 13: 1750–1756.
25. Duff HJ, Offord J, West J, et al. Class I and IV antiarrhythmic drugs and cytosolic calcium regulate mRNA encoding the sodium channel alpha subunit in rat cardiac muscle. *Mol Pharmacol* 1992; 42: 570–574.
26. Hsieh YC, Hung CY, Li CH, et al. Angiotensin-receptor blocker, angiotensin-converting enzyme inhibitor, and risks of atrial fibrillation: A nationwide cohort study. *Medicine (Baltimore)* 2016; 95: e3721.
27. Li Y, Niu HY, Liu N, et al. Effect of imidapril on the effective refractory period and sodium current of ventricular noninfarction zone in healed myocardial infarction. *Yao Xue Xue Bao* 2005; 40: 654–658.
28. Nattel S, Shirotshita-Takeshita A, Brundel BJ, et al. Mechanisms of atrial fibrillation: Lessons from animal models. *Prog Cardiovasc Dis* 2005; 48: 9–28.
29. Weigt HU, Kwok WM, Rehmert GC, et al. Voltage-dependent effects of volatile anesthetics on cardiac sodium current. *Anesth Analg* 1997; 84: 285–293.
30. Chen L, Li QY, Yang Y, et al. Inhibitory effects of tetrandrine on the Na(+) channel of human atrial fibrillation myocardium. *Acta Pharmacol Sin* 2009; 30: 166–174.
31. Kim HK, Youn JB, Lee SR, et al. The angiotensin receptor blocker and PPAR-γ agonist, telmisartan, delays inactivation of voltage-gated sodium channel in rat heart: Novel mechanism of drug action. *Pflugers Arch* 2012; 464: 631–643.